ALNYLAM PHARMACEUTICALS, INC. (ALNY) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.34M; Additional Paid in Capital, Common StockUSD $7.72B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-32.14M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD (m); Additional Paid in Capital, Common StockUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m).
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.32M; Additional Paid in Capital, Common StockUSD $7.51B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-20.10M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.32M; Additional Paid in Capital, Common StockUSD $7.41B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-21.77M.
ALNYLAM PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Preferred Stock, Value, Outstanding USD | Common Stock, Value, Outstanding USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.34M | $7.72B | $-32.14M | $-6.33B | $1.35B | 3 month · $87.73M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | (m) | $1.08B | 3 month · $71.26M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $1.32M | $7.51B | $-20.10M | $-6.70B | $789.18M | 12 month · $352.75M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $1.32M | $7.41B | $-21.77M | $-7.16B | $233.89M | 3 month · $109.34M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $1.31M | $7.69B | $-29.95M | $-7.41B | $555.35M | 3 month · $112.81M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $1.30M | $7.50B | $-37.52M | $-7.35B | $426.14M | 3 month · $57.84M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $1.29M | $7.39B | $-34.52M | $-7.29B | $67.09M | 12 month · $275.32M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $1.29M | $7.26B | $-24.83M | $-7.20B | $32.35M | 3 month · $46.61M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $1.28M | $7.12B | $-34.64M | $-7.09B | $-3.07M | 3 month · $90.10M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $1.26M | $6.88B | $-26.99M | $-7.08B | $-219.27M | 3 month · $46.16M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $1.26M | $6.81B | $-23.38M | $-7.01B | $-220.64M | 12 month · $225.87M | (m) | (m) | $0.00 | $1.26M | (m) | (m) |
| 2023-09-30 | $0.00 | $1.25M | $6.74B | $-32.34M | $-6.87B | $-165.87M | 3 month · $64.87M | (m) | (m) | (m) | (m) | 9 month · $-3.97M | (m) |
| 2023-06-30 | $0.00 | $1.25M | $6.65B | $-37.08M | $-7.02B | $-408.13M | 3 month · $76.99M | (m) | (m) | (m) | (m) | 6 month · $-2.10M | (m) |
| 2023-03-31 | $0.00 | $1.24M | $6.52B | $-39.12M | $-6.74B | $-259.24M | 3 month · $41.14M | (m) | (m) | (m) | (m) | 3 month · $-4.13M | (m) |
| 2022-12-31 | $0.00 | $1.24M | $6.45B | $-44.65M | $-6.57B | $-158.22M | 12 month · $237.40M | (m) | (m) | $0.00 | $1.24M | 12 month · $6.13M | (m) |
| 2022-09-30 | $0.00 | $1.23M | $6.34B | $-43.78M | $-6.36B | $-67.64M | 3 month · $129.13M | (m) | (m) | (m) | (m) | 9 month · $10.91M | (m) |
| 2022-06-30 | $0.00 | $1.21M | $6.17B | $-42.22M | $-5.96B | $176.04M | 3 month · $34.45M | (m) | (m) | (m) | (m) | 6 month · $8.89M | (m) |
| 2022-03-31 | $0.00 | $1.21M | $6.12B | $-38.06M | $-5.68B | $401.17M | 3 month · $30.05M | (m) | (m) | (m) | (m) | 3 month · $7.18M | (m) |
| 2021-12-31 | $0.00 | $1.20M | $6.06B | $-33.26M | $-5.44B | $588.20M | 12 month · $168.30M | (m) | (m) | (m) | (m) | 12 month · $1.93M | (m) |
| 2021-09-30 | $0.00 | $1.20M | $5.97B | $-34.23M | $-5.18B | $755.89M | 3 month · $33.70M | (m) | (m) | (m) | (m) | 9 month · $-81.00K | (m) |
| 2021-06-30 | $0.00 | $1.19M | $5.86B | $-36.08M | $-4.98B | $853.36M | 3 month · $32.93M | (m) | (m) | (m) | (m) | 6 month · $133.00K | (m) |
| 2021-03-31 | $0.00 | $1.17M | $5.75B | $-36.72M | $-4.79B | $926.19M | 3 month · $56.30M | (m) | (m) | (m) | (m) | 3 month · $-58.00K | (m) |
| 2020-12-31 | $0.00 | $1.16M | $5.64B | $-43.62M | $-4.59B | $1.02B | 12 month · $142.99M | (m) | (m) | (m) | (m) | 12 month · $-522.00K | (m) |
| 2020-09-30 | $0.00 | $1.16M | $5.59B | $-37.19M | $-4.34B | $1.22B | 3 month · $40.23M | (m) | (m) | (m) | (m) | 9 month · $-983.00K | (m) |
| 2020-06-30 | $0.00 | $1.16M | $5.52B | $-33.21M | $-4.09B | $1.40B | 3 month · $33.71M | (m) | (m) | (m) | (m) | 6 month · $-257.00K | (m) |
| 2020-03-31 | $0.00 | $1.13M | $5.29B | $-32.06M | $-3.91B | $1.35B | 3 month · $34.58M | (m) | (m) | (m) | (m) | 3 month · $-2.80M | (m) |
| 2019-12-31 | $0.00 | $1.12M | $5.20B | $-36.52M | $-3.73B | $1.44B | 12 month · $177.23M | (m) | (m) | (m) | (m) | 12 month · $-677.00K | (m) |
| 2019-09-30 | $0.00 | $1.11M | $5.09B | $-34.37M | $-3.45B | $1.61B | 3 month · $46.66M | (m) | (m) | (m) | (m) | 9 month · $-484.00K | (m) |
| 2019-06-30 | (m) | $1.11M | $5.03B | $-35.83M | $-3.24B | $1.76B | 3 month · $30.80M 6 month · $63.34M | (m) | (m) | (m) | (m) | 6 month · $-344.00K | (m) |
| 2019-03-31 | (m) | $1.06M | $4.60B | $-32.85M | $-3.02B | $1.55B | 3 month · $32.54M | (m) | (m) | (m) | (m) | 3 month · $-14.00K | (m) |
| 2018-12-31 | $0.00 | $1.01M | $4.18B | $-33.21M | $-2.84B | $1.30B | 12 month · $158.64M | (m) | (m) | (m) | (m) | 12 month · $-1.63M | (m) |
| 2018-09-30 | (m) | $1.01M | $4.14B | $-33.39M | $-2.63B | $1.48B | 3 month · $88.41M | (m) | (m) | (m) | (m) | 9 month · $-1.63M | (m) |
| 2018-06-30 | (m) | $1.00M | $4.04B | $-33.81M | $-2.38B | $1.62B | 3 month · $22.00M 6 month · $41.46M | (m) | (m) | (m) | (m) | 6 month · $557.00K | (m) |
| 2018-03-31 | (m) | $1.00M | $4.01B | $-34.85M | $-2.22B | $1.75B | 3 month · $19.46M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-01-01 | (m) | (m) | (m) | (m) | $-2.08B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $997.00K | $3.95B | $-34.43M | $-2.15B | $1.77B | 12 month · $91.32M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $924.00K | $3.10B | $-33.74M | $-2.01B | $1.06B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $917.00K | $3.04B | $-33.96M | $-1.88B | $1.12B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $861.00K | $2.63B | $-33.83M | $-1.76B | $830.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $859.00K | $2.61B | $-33.44M | $-1.66B | $920.22M | 12 month · $74.18M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $858.00K | $2.59B | $-27.78M | $-1.54B | $1.01B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $856.00K | $2.57B | $-28.30M | $-1.44B | $1.10B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $855.00K | $2.55B | $-9.01M | $-1.35B | $1.19B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $851.00K | $2.51B | $4.37M | $-1.25B | $1.26B | 12 month · $45.78M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $847.00K | $2.48B | $-7.22M | $-1.16B | $1.32B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $845.00K | $2.47B | $18.76M | $-1.08B | $1.41B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $842.00K | $2.45B | $52.38M | $-1.01B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $772.00K | $1.84B | $48.76M | $-956.63M | $936.27M | 12 month · $33.06M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $767.00K | $1.82B | $15.19M | $-935.24M | $904.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $763.00K | $1.81B | $21.98M | $-891.25M | $942.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $755.00K | $1.78B | $25.03M | $-847.18M | $954.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $637.00K | $846.23M | $19.72M | $-596.24M | $270.35M | 12 month · $20.70M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $632.00K | $833.66M | $27.17M | $-563.88M | $297.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $624.00K | $813.61M | $28.13M | $-534.19M | $308.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $621.00K | $806.14M | $20.82M | $-516.02M | $311.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $525.00K | $624.88M | $15.66M | $-507.01M | $134.05M | 12 month · $12.36M | $15.70M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $524.00K | $621.35M | $108.00K | $-444.82M | $177.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $520.00K | $613.15M | $-62.00K | $-425.32M | $188.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $519.00K | $609.26M | $-37.00K | $-412.36M | $197.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $427.00K | $518.73M | $-165.00K | $-401.00M | $118.00M | 12 month · $16.68M | (m) | (m) | (m) | (m) | (m) | 12 month · $120.00K |
| 2011-09-30 | (m) | $427.00K | $514.29M | $-151.00K | $-386.69M | $127.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $0.00 | $427.00K | $509.83M | $-246.00K | $-373.46M | $136.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $0.00 | $424.00K | $504.79M | $-18.00K | $-359.63M | $145.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $0.00 | $423.00K | $500.44M | $714.00K | $-343.35M | $158.23M | 12 month · $19.12M | (m) | $158.23M | (m) | (m) | (m) | 12 month · $220.00K |
| 2010-09-30 | $0.00 | $422.00K | $495.35M | $1.29M | $-336.42M | $160.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $0.00 | $421.00K | $490.56M | $1.29M | $-326.79M | $165.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $0.00 | $418.00K | $476.66M | $716.00K | $-299.83M | $177.97M | 12 month · $19.73M | (m) | $177.97M | (m) | (m) | (m) | 12 month · $441.00K |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $202.12M | 12 month · $16.38M | (m) | $202.12M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $199.17M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |